1. Background
Colon cancer is the third leading cause of cancer-related deaths in the United States. Globally, it is the fourth leading cause of death among all cancers (1, 2). Breast cancer is considered the second cause of mortality in women worldwide (3). Surgery, chemotherapy, radiotherapy, immunotherapy, and hormone therapy are the main tools of cancer treatment; however, they show considerable adverse effects (4). Conventional chemotherapy bears side effects due to non-specific effects on normal tissues and the development of multidrug resistance in tumors (5). To overcome these problems, various plant-derived anti-cancer agents are available for clinical use owing to their diverse biological functions, as well as minimal side effects on normal tissues (6). Curcumin, a flavonoid, is extracted from the rhizomes of Curcuma langa and shows anti-oxidative and anti-inflammatory properties, as well as anti-proliferative effects against several cancer cells (7). However, its limited systemic bioavailability restricts its application as an oral therapeutic agent. To address this limitation, nanoparticulated-drug delivery systems have been widely used in order to deliver anti-cancer agents to tumors. Iron oxide nanoparticles (IONPs) have received great attention due to their ability to carry hydrophobic drugs, excellent biodegradability and biocompatibility, and a controlled drug release profile (8, 9).
In the field of cancer therapy, drug delivery systems increase the effectiveness of drugs. Targeted drug delivery systems are generally referred to as carriers capable of binding to or holding and carrying drugs in the body. Nanostructures can penetrate into cancerous tissues, specifically through either passive (such as enhanced permeability and the retention effect) or active (for example by binding to ligands such as small molecules, peptides, or antibodies) transport systems (10, 11). However, agglomeration has limited the application of these nanoparticles (12), which has been resolved using surface functionalizing compounds, including sodium alginate (NaAlg) and hydroxy apatite (HAp). These compounds, as natural inorganic materials, present excellent and favorable biocompatibility, biodegradability, and osteoconductivity properties (13). These are non-toxic polymers widely used as biomaterials in this regard. Therefore, the purpose of the current research was to develop a drug delivery system based on coated IONPs to enhance the therapeutic efficacy of curcumin. We evaluated the physicochemical properties of the nanoparticles (NPs) and determined the drug release profile. The anti-cancer effects of the nano-formulations were assessed against the HT-29 and MCF-7 cell lines, representing colon and breast cancers, respectively.
2. Objectives
The main purpose of this study was to evaluate and compare the cytotoxic effects of curcumin-loaded IONPs and free curcumin against the HT-29 (colon) and MCF-7 (breast) cancer cell lines.
3. Methods
3.1. Materials
Curcumin, calcium nitrate tetra hydrate Ca (NO3)2. 4H2O, diammonium hydrogen phosphate (NH4)2HPO4, iron (III) chloride (FeCl3), ferrous sulphateheptahydrate (FeSO4.7H2O), MTT reagent, and TWEEN® 80 were purchased from Sigma-Aldrich (USA). Ethanol (EtOH, ≥ 99.8%, HPLC), methanol anhydrous (MeOH, 99.8%), alginic acid sodium salt (NaAlg, low viscosity), and dimethylnsulfoxide (DMSO) were purchased from Merck (Germany). The HT-29 and MCF-7 cancer cell lines were purchased from Pastor Institute Cell bank (Iran, Tehran).
3.2. Synthesis of HAP- and NaAlg-coated IONPs
Iron oxide nanoparticles were synthesized by the co-precipitation technique. Briefly, 3.2 g FeCl3 and 2.78 g FeSO4 were dissolved in distilled water, and NaOH solution was then added to the solution. A 20-minute degassing was performed under nitrogen atmosphere. The resulting precipitate was collected magnetically, washed with deionized water several times, and then dried. The obtained product was used for HAp and NaAlg coating. Then 0.5 g of IONPs was dissolved in distilled water and mixed with NaAlg powder and 0.25 M Ca (NO3)2 and (NH4)2HPO4. The pH of the system was maintained in the range of 8-9. Finally, the resultant was washed 2 - 3 times with deionized water (12).
3.3. In Vitro Loading of Curcumin into IONPs
For the loading of curcumin into IONPs coated with HAP-NaAlg, 5 mg of curcumin was dissolved in acetone and added dropwise to 20 mg of an IONP/HAP-NaAlg aqueous suspension, followed by stirring at 400 rpm for 24 h to allow curcumin to permeate into the NPs. At the end, the resulting mixture was washed to separate free curcumin from the coated IONPs containing curcumin (14).
3.4. Drug Loading and Encapsulation Efficiency
Free curcumin level was determined in the supernatant obtained after the production of the NPs. To evaluate drug loading (DL) efficiency, the NPs were centrifuged at 11,000 rpm and 4°C for 30 minutes, and the resulting suspension was used for calculating DL amount. Also, the amount of free curcumin was determined by UV-Vis spectrophotometry at 450 nm (14). The measurement was repeated three times. Encapsulation efficiency (EE) and DL were calculated as follows:
3.5. Scanning Electron Microscopy
To evaluate surface morphology, scanning electron microscopy (SEM) (Philips XL30, the Netherlands) was used.
3.6. Transmission Electron Microscopy
To evaluate the size of IONPs, transmission electron microscopy (TEM) (JEOL, Tokyo, Japan) was used. A drop of IONP suspension was placed on a carbon coated copper TEM grid and allowed to air-dry. The dried samples were then examined at 120 kV under the microscope.
3.7. Fourier Transform Infrared Spectroscopy
For Fourier transform infrared (FTIR) spectroscopy analysis, IONPs, NaAlg/HAP, IONPs@NaAlg/HAP, curcumin, and IONPs@NaAlg/HAP-curcumin were scanned over a wave range of 4000 - 400 cm-1 using an FTIR spectrophotometer (Perkin Elmer 65, USA) to determine possible chemical bonds between the drug and NPs.
3.8. X-ray Diffraction Study
To determine the crystalline structure of the IONPs, X-ray diffraction (XRD) patterns were measured. The experiment was performed by a D/Max-B Rikagu diffractometer (AW-XDM300, the UK). All the experiments were performed at room temperature.
3.9. In Vitro Drug Release
To measure the in vitro release of curcumin from IONPs, 3 mg of the sample was transferred into 6 mL of PBS (pH = 7.5 or 5.5) containing 0.1% w/v Tween-80 and stirred at 100 rpm and 37°C. At certain time points, 1 mL of the solution was replaced with the same amount of fresh PBS. The mixture was then centrifuged (8000 rpm, 25 min). The absorbance of each sample was measured by an UV-Visible spectrophotometer at 450 nm, and the concentration of curcumin released from IONPs was determined using a standard calibration curve (14).
3.10. In Vitro Cytotoxicity Assessment
The cytotoxic effects of coated IONPs, free curcumin, and curcumin-loaded IONPs were assessed against the HT-29 and MCF-7 cancer cell lines by the MTT assay. Briefly, cells were plated at a density of 1 × 104 cells per well in 96-well plates and cultivated at 37°C in humidified air containing 5% CO2 (Heal Force HF-90, Japan) for 24 h. Then the cells were treated with various concentrations (20 - 80 µg/mL) of coated IONPs, free curcumin, and curcumin-loaded IONPs and incubated for 24, 48, and 72 h at 37°C (14). After the specified incubation time, the culture medium was discarded, and 20 µL of MTT (5 mg/mL) solution was added to each well, and incubation continued for 4 h at 37°C. The supernatant was withdrawn, and 150 µL DMSO was added to each well to dissolve formazan crystals. The UV absorption of soluble formazan crystals was determined using spectrophotometry at 570 nm by a microplate reader. The experiment was performed in triplicate (15). The viability of the cells was calculated using the following equation:
Where Abstest cells and Abscontrol cells are the amount of formazan in treated and non-treated cells, respectively.
3.11. Flow Cytometry
For apoptosis assessment, HT-29 and MCF-7 cells were treated for 72 hours. After washing with PBS and trypsin, the cells were separated from the culture medium by centrifugation. The cells were washed with the buffer solution and centrifuged at 15,000 rpm for 15 minutes. After that, 5 µL of annexin-V (BD Pharmingen) and Propidium iodide were added to the cells, and the cells were incubated for 15 minutes at room temperature in dark and then evaluated by flow cytometry (BD FACS Calibur) (16).
3.12. Statistical Analysis
All results were expressed as mean ± SD. Statistical analysis was conducted by one-way ANOVA, and p values less than 0.05 were considered statistically significant.
4. Results
4.1. IONPs’ Characterization
4.1.1. Assessment of DL Efficiency
Drug encapsulation efficiency is an important factor to investigate the performance of drug carriers. Curcumin-encapsulated IONPs were prepared 21.03 ± 0.87 drug loaded in the nanoparticles and showed 84.16 ± 3.51 % encapsulation efficiency.
4.1.2. SEM and TEM Analyses
The results of SEM showed that the prepared NPs were spherical in shape and relatively monodisperse in size (Figure 1A). Also, TEM results showed spherical and smooth surfaces in NPs with an average particle size of 5 - 7 nm. (Figure 1B). No aggregation or adhesion was observed in microscopic images. Although the particles seemed to be agglomerated in electron microscopy analysis, this was probably due to the dry state of the NPs, which could be easily resolved in water to obtain separate particles or less accumulation.
Figure 1.
A, SEM images and B, TEM images of iron oxide nanoparticles.
4.1.3. FTIR Analysis
The FTIR spectra of NaAlg/HAP, IONPs@NaAlg/HAP, curcumin, and IONPs@NaAlg/HAP-curcumin after absorption have been shown in Figure 2. The FTIR spectrum of the IONPs showed significant absorption bands around 630 and 3423 cm-1, which are related to the tensile vibration of the Fe-O and O-H groups of IONPs. In the FTIR spectrum of HAp-NaAlg nanoparticles, the absorption peaks around 570, 1046, 1384, 1637, and 3426 cm-1 were related to the stretching modes of the O-H group (17). The FTIR spectrum of IONPs@HAP/NaAlg particles showed the apparent interactions of sodium alginate with both hydroxyapatite and IONPs, characterized by COOH symmetrical and asymmetrical tensile vibrations at 1625 cm-1 and 1384 cm-1, respectively (18, 19). As shown, the spectrum of IONPs had three absorption peaks around 583, 1627, and 3423 cm-1, with the highest absorption intensity at 583 cm-1. The diagrams of the hydroxyapatite and sodium alginate coatings also showed absorption peaks around 823, 562, 1046, 1384, 1637, 3426, 2005, and 3426 cm-1, with the latest two showing the highest absorption. The spectrum of the IONPs coated with hydroxyapatite, and sodium alginate demonstrated absorption peaks at 563, 1030, 1625, 2005, 2923, and 3424 cm-1, with more intensity at the wave numbers of 563, 1030, and 3424 cm-1. Strong absorption around 563 cm-1 was due to the crystal structure of iron oxide. On the other hand, a significant absorption at 3424 cm-1 resulted from the overlap of 3423 cm-1 (related to pure IONPs) and 3426 cm-1 (related to hydroxyapatite and sodium alginate) absorption peaks. Other absorption peaks observed in the spectrum of the IONPs coated with hydroxyapatite and sodium alginate, such as 1030 cm-1 and 2005 cm-1, are very similar to those of hydroxyapatite and sodium alginate, all of which indicated the success of the coating process. The correct coating of hydroxyapatite and sodium alginate depends on the iron nano oxide sample. Similarly, the main absorption peaks around 1200, 1400, 1600, 2800, and 3400 cm-1 were in fact due to overlapping peaks. These main absorption peaks corresponded to the iron oxide sample coated with hydroxyapatite and sodium alginate, which were both loaded with curcumin. The absorption peaks indicated that the NPs were successfully coated and then loaded with curcumin.
Figure 2.
Comparison of the FTIR spectra of HAP and NaAlg (green), IONPs/HAP-NaAlg (yellow), curcumin (red), and IONPs/HAP-NaAlg/curcumin (blue).
4.1.4. XRD Analysis
The XRD patterns of the IONPs have been depicted in Figure 3, the XRD pattern at 2θ of 30.1, 35.6, 43.3, 53.5, 57.63, and 74 demonstrated that the synthesized magnetic NPs had a crystal structure. The XRD pattern confirmed the crystallography and different phases of the studied NP formulations (20).
Figure 3.
The X-ray diffraction pattern of IONPS.
4.1.5. In Vitro Drug Release
Figure 4 represents curcumin release pattern from coated IONPs at two different pH (5.5 and 7.5). The results demonstrated an abrupt release during the first 20 to 24 hours at both pH, which then continued steadily for 240 hours. However, the amount of released curcumin was higher at pH 5.5, followed by a more gradual release at longer periods of time until reaching a release percentage of 96.77 ± 0.68% while this rate was about 44.24 ± 0.59% at pH = 7.5. This may be explained by the slow degradation of HAp-coated materials in acidic media. Since cancerous cells have a pH lower than that of normal cells, this faster release at the lower pH can enhance the effectiveness of targeting tumors and drug release into tumor microenvironment (21).
Figure 4.
In vitro cumulative release percentage of curcumin% from IONPs/HAP-NaAlg under two buffer conditions (pH = 5.5 and 7.5).
4.1.6. In Vitro Cytotoxicity
The in vitro cytotoxic effects of HAP/NaAlg-coated IONPs, free curcumin, and curcumin-loaded IONPs were assessed against the HT-29 and MCF-7 cancer cell lines by the MTT test after 24, 48, and 72 h of treatment. No obvious cytotoxicity was observed for the IONPs coated with HAP/NaAlg at the studied concentrations. Both free curcumin and curcumin-loaded IONPs exhibited concentration- and time-dependent cytotoxicity. The anti-proliferative effect of curcumin-loaded IONPs was significantly higher than that of free curcumin at the same concentration and incubation time (Figures 5 and 6).
Figure 5.
Viability of the HT-29 cells treated with 20, 40, 60, and 80 µg/mL of (A) curcumin, (B) coated IONPs, and (C) curcumin-loaded coated IONPs for 24, 48, and 72 h (mean ± SD, P-value < 0.001).
Figure 6.
Viability of the MCF-7 cells treated with 20, 40, 60, and 80 µg/mL of A, Curcumin; B, Coated IONPs; and C, Curcumin-loaded coated IONPs for 24, 48, and 72 h (mean ± SD, P-value < 0.001).
The results showed that at 24, 48, and 72 hours after treating the cell lines with curcumin-loaded IONPs, the mean percentage of cell survival at all concentrations was significantly different compared with the control group (P < 0.001).
Higher IC50 values (Tables 1 and 2), as the drug concentration required to inhibit the growth of 50% of tumor cells (HT-29 and MCF-7) during a certain period, were obtained for free curcumin and curcumin-loaded coated IONPs, confirming the higher cytotoxic effects of curcumin-loaded IONPs.
Table 1.The IC50 Values of Free Curcumin and Curcumin-Loaded Coated IONPs Against the HT-29 Cell Line After 24, 48, and 72 h of Incubation (N = 3)a
| IC50 (µg/mL) HT-29 Cell Line | ||
|---|---|---|
| Time, h | Curcumin | Curcumin-Loaded Coated IONPs |
| 24 | 1.18 ± 120.23 | 1.15 ± 79.04 |
| 48 | 1.15 ± 86.04 | 1.15 ± 57.62 |
| 72 | 1.13 ± 62.66 | 1.12 ± 42.14 |
aValues are expressed as mean ± SD.
Table 2.The IC50 Values of Free Curcumin and Curcumin-Loaded Coated IONPs Against the MCF-7 Cell Line After 24, 48, and 72 h of Incubation (N = 3)a
| IC50 (µg/mL) MCF-7 Cell Line | ||
|---|---|---|
| Time, h | Curcumin | Curcumin Loaded Coated IONPs |
| 24 | 1.17 ± 136.14 | 1.13 ± 103.97 |
| 48 | 1.15 ± 98.93 | 1.14 ± 70.29 |
| 72 | 1.13 ± 67.16 | 1.12 ± 46.86 |
aValues are expressed as mean ± SD.
4.1.7. Flow Cytometry
The results of annexin/PI staining to determine alive/apoptotic/late apoptotic/dead HT-29 and MCF-7 cells have been presented in Figures 7 and 8, respectively. The results showed that in comparison with free curcumin, the cells treated with curcumin-loaded HAp/NaAlg-coated IONPs showed a higher percentage of cells in either the late-apoptosis, necrosis, or death phases.
Regarding the HT-29 cell line, the percentage of alive cells in the control group was 87.4%, which was higher than that of other groups. The percentage of apoptotic cells increased from 9.20% in the cells incubated with curcumin to 44.1% in those incubated with curcumin-loaded HAp/NaAlg-coated IONPs. Moreover, the percentage of cells in late apoptosis rose from 6.82% in the cells incubated with curcumin to 11.2% in the cells incubated with curcumin-loaded HAp/NaAlg-coated IONPs.
Figure 7.
Flow cytometric analysis of HT-29 cells. A, Control group; B, Curcumin; and C, Curcumin-loaded coated IONPs.
Figure 8.
Flow cytometric analysis of MCF-7 cells. A, Control group; B, Curcumin; and C, curcumin-loaded coated IONPs.
For MCF-7 cells, the percentage of alive cells in the control group was 78.3%, which was higher compared to other groups. The percentage of apoptotic cells increased from 1.22% in the cells incubated with curcumin to 12.9% in those incubated with curcumin-loaded HAp/NaAlg-coated IONPs. Moreover, the percentage of cells in late apoptosis rose from 10.8% in the cells incubated with curcumin to 20.3% in the cells incubated with curcumin-loaded IONPs-HAp-NaAlg.
5. Discussion
The significant cytotoxic activity of curcumin against various human cancer cells has been reported in the literature. Curcumin exerts its anti-cancer activity in various ways and by interfering with intracellular signaling pathways. Curcumin can induce or inhibit the production of a variety of cytokines and enzymes, such as MAPK, NFkB, COX-2, and IkKβ (22). Nevertheless, curcumin is extremely hydrophobic, which is a major obstacle to its successful application as a therapeutic agent.
In order to resolve this limitation, structural modifications and targeted drug delivery systems can be used. Iron oxide nanoparticles can deliver various anti-cancer compounds, such as chemotherapeutics, peptides, and active compounds, to tumor cells in a dose-dependent manner, reducing drug-induced toxicity towards healthy cells. These nanoparticles have been utilized to suppress the growth of tumor cells.
This study was carried out to improve curcumin bioavailability without influencing its biological properties, by loading it into IONPs, which were successfully prepared by the co-precipitation technique. Particle size is considered an important factor in determining the efficacy of drug delivery systems because it affects the pharmaceutical properties of the drug, including its release profile and cellular uptake. In this study, the high drug loading and entrapment efficiency ensured the successful preparation of curcumin-loaded IONPs, suggesting a strong interaction between curcumin, as a hydrophobic drug, and hydroxyapatite-coated IONPs (18). The FTIR analysis revealed no chemical interaction between IONPs and curcumin, ensuring that curcumin could be entrapped into the NPs without alteration in its natural structure. The XRD pattern confirmed the crystalline nature of the synthesized IONPs. The maximum release rate of curcumin was observed at pH = 5.5, suggesting that the release process could be facilitated by the slow degradation of HAp-coating materials in acidic media (20, 23). Since cancerous cells have pH lower than normal cells, this faster release at the lower pH can be beneficial for targeting tumors because of their acidic microenvironments.
The therapeutic efficacy of a drug strongly depends on its concentration and duration of availability at the tumor site. In the present study, the sustained release observed indicated that the coated IONPs could be suitable carriers for targeting tumors by allowing sustained and prolonged release of curcumin, boosting its therapeutic effects (8). Our results demonstrated that IONPs alone had no cytotoxic effects, ensuring their biosafety and non-toxic nature. The relatively low IC50 values of curcumin-loaded coated IONPs against the evaluated cancer cell lines are probably due to the small size of the NPs and the controlled release of curcumin from the nano-carriers compared to the rapid release of neat drugs. Our results showed that after 24, 48, and 72 hours of treating the cell lines with curcumin-loaded coated IONPs, the mean percentage of cell survival at all concentrations was significantly different from that of the control group (P < 0.001). Consistent with the results of this study, Thu et al. (8) showed the higher efficacy of Fe3O4/OCMCs/Cur against the HT-29 cancer cell line (8). In vivo studies on Balb/c mice showed a considerable decline in tumor development and increased survival in tumor bearing mice treated with cisplatin-loaded IONPs (24).
Preclinical and clinical studies on IONPs have demonstrated a complex interaction between these NPs and the immune system, depending on the properties of the NPs and the type and condition of the host. Iron oxide nanoparticles have had a variety of useful primary applications; however, for being used in clinical settings, there is a need for more studies on animal models and evaluating preclinical results (25). Our results indicated that the curcumin-loaded IONPs had a considerably higher ability to induce apoptosis in cancerous cells compared to free curcumin, probably due to the higher uptake of the drug-loaded NPs (26).
5.1. Conclusions
Nanotechnology in the field of pharmaceutics seeks new models for targeted drug delivery to tumor cells, which is more effective in suppressing cancer progression and reducing drug side effects. Therefore, it is essential to find anti-tumor compounds that have fewer side effects, and herbal medicines are among these compounds.
In the present study, IONPs were synthesized, coated with HAp/NaAlg, and then loaded with curcumin. Curcumin release was measured for 10 days, which showed a faster release in acidic pH (i.e., mimicking tumor microenvironment). Anti-proliferative tests showed that IONPs@HAP-NaAlg@Curcumin had high cytotoxicity against colon and breast cancer cells, with IC50 values lower than that of free curcumin. Flow cytometry results also confirmed the results of the MTT assay, indicating that curcumin-coated IONPs increased the rate of apoptosis in the cancer cell lines.
Curcumin-coated IONPs showed good cytotoxic effects against both HT-29 and MCF-7 cells, and this effect was more prominent against HT-29 cells. Therefore, this formulation can be regarded as an anti-tumor compound for treating various cancers, including colon and breast cancers. Before conducting clinical trials in humans, experimental studies should be performed on large rodents.
